MicroTech Medical (Hangzhou) (HKG:2235) said Chinese regulators expanded the scope of its Equil patch insulin pump to include the treatment of children, according to a Hong Kong bourse filing Wednesday.
Shares of the medical firm gained nearly 3% in morning trade Thursday.
The approval covers the treatment's use in children and adolescents aged 3 years to 17 years, and was previously approved to treat adult diabetic patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.